InflaRx (IFRX) N.V.announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria, CSU, and hidradenitis suppurativa, HS, investigating the Company’s oral C5aR inhibitor, INF904.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter